ViroCell Biologics Completes Oversubscribed Financing

Contributed by: Business Wire

Logo

Tags

Stem Cells

Biotechnology

Manufacturing

Health

Pharmaceutical

Oncology

Research

Other Manufacturing

Genetics

Science

Clinical Trials

Oversubscribed Financing

More Like This

ViroCell Biologics Signs Master Services Agreement With Prominent NCI-Designated Cancer Center

ViroCell Biologics to Host Panel Event at 2024 Cell & Gene Meeting on the Mesa

ViroCell and Great Ormond Street Hospital Poised to Unlock Clinical Trial ‘Backlog’ Following MHRA Manufacturing Approval

ViroCell to present at 2024 Cell & Gene Meeting on the Med

Merck operators monitoring viral vector production in a bioreactor in Merck's Carlsbad, California manufacturing facility. (Photo: Business Wire)

Merck Signs Definitive Agreement to Acquire Mirus Bio, Furthering Ambition to Be a Leading Supplier for Viral Vector Manufacturing

PR Newswire associated0

EnGeneIC Selects Global CDMO BioCina to Advance Their Ground-Breaking Cancer Treatment

Ori Biotech Unveils IRO Platform at Annual International Society for Cell & Gene Therapy Conference

Viromed Medical AG Plans to Acquire All Shares of ActivCell Group AG by Way of a Capital Increase Against Contribution in Kind with Exclusion of Subscription Rights